The US Food and Drug Administration (FDA) has granted approval for Shorla Oncology’s Nelarabine Injection, an oncology drug, to treat T-cell leukaemia, an aggressive blood and bone marrow cancer that progresses quickly.
The oncology drug has been approved to treat T-cell Lymphoblastic Lymphoma (T-LBL) and T-cell Acute Lymphoblastic Leukemia (T-ALL). It offers an alternative to a product for which there is a shortage.
Read more at:
https://www.pharmaceutical-technology.com/news/fda-shorla-t-cell-leukaemia/
